Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
XLO

XLO - Xilio Therapeutics, Inc. Stock Price, Fair Value and News

$0.81-0.04 (-4.71%)
Delayed as of 15 May 2025, 02:58 pm ET
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

XLO Price Action

Last 7 days

26.9%

Last 30 days

19.7%

Last 90 days

-34.1%

Trailing 12 Months

-22.0%

XLO RSI Chart

XLO Valuation

Market Cap

44.0M

Price/Earnings (Trailing)

-0.81

Price/Sales (Trailing)

6.94

Price/Free Cashflow

2.09

XLO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

XLO Fundamentals

XLO Revenue

Revenue (TTM)

6.3M

XLO Earnings

Earnings (TTM)

-54.3M

Earnings Growth (Yr)

22.89%

Earnings Growth (Qtr)

-1.31%

XLO Profitability

Return on Equity

-507.5%

Return on Assets

-52.36%

Free Cashflow Yield

47.86%

XLO Investor Care

Shares Dilution (1Y)

40.28%

Diluted EPS (TTM)

-0.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240006.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About Xilio Therapeutics, Inc.

XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEhttps://xiliotx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES84

Xilio Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Xilio Therapeutics, Inc.? What does XLO stand for in stocks?

XLO is the stock ticker symbol of Xilio Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xilio Therapeutics, Inc. (XLO)?

As of Wed May 14 2025, market cap of Xilio Therapeutics, Inc. is 44.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XLO stock?

You can check XLO's fair value in chart for subscribers.

Is Xilio Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether XLO is over valued or under valued. Whether Xilio Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Xilio Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XLO.

What is Xilio Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 14 2025, XLO's PE ratio (Price to Earnings) is -0.81 and Price to Sales (PS) ratio is 6.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XLO PE ratio will change depending on the future growth rate expectations of investors.